Thursday, 20 Sep 2018

You are here

Ixekizumab (Taltz) FDA Approved for Psoriatic Arthritis

On Friday, December 1st, the FDA approved Lilly's drug Taltz (ixekizumab) for use in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Christi Shaw, president, Lilly Bio-Medicines. estimates that PsA affects 1.6 million Americans. Taltz, an IL-17 inhibitor, has previously been approved for plaque psoriasis where it has shown high level PASI75 and PASI100 responses.

The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. For those psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, the dosing regimen for plaque psoriasis is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.

Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate.

Product label warnings include the usual low level risk of infection, the need for TB screening and the unique risk of colitis or colitis exacerbation - few cases of Crohn's disease (0.1%) and ulcerative colitis (0.2%) were seen in Taltz treated patient but not placebo controls.  Other common, nonserious side effects include njection site reactions, upper respiratory tract infections, nausea, and tinea infections. Necessary vaccines should be given prior to ixekizumab initiation and live virus vaccines should be avoided. 

The efficacy and safety of Taltz was determined from findings from two randomized, double-blind, placebo-controlled phase 3 studies – SPIRIT-P1 and SPIRIT-P2 – which included more than 670 adult patients with active PsA. SPIRIT-P1 was done in biologic naive PsA patients and SPIRIT-P2 included patients with prior use of a tumor necrosis factor inhibitor (TNFi). Compared to placebo, the ACR20 response rates was 58% in SPIRIT-P1 (30% PBO) and 53% in SPIRIT-P2 (20% PBO).

"For patients with PsA, treatment goals often include improvement in joint symptoms," said Philip Mease, M.D., Swedish Medical Center and University of Washington. "Based on the study results, Taltz can provide significant improvement in joint symptoms for patients who had never been treated with a biologic disease-modifying antirheumatic drug as well as patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors." 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Biologic Therapies Improve Work Outcomes in Spondyloarthritis

A study from the British Society for Rheumatology Biologics Register in Axial Spondyloarthritis (BSRBR-AS) shows that biologic use significantly improves work productivity and overall activity impairment.

 

The BSRBR-AS registry analyzed 577 participants who were employed;  28% were started on biological therapy .

BMS Tyk 2 Inhibitor Benefits Psoriasis

The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.

Methotrexate's Low Efficacy in Cutaneous Psoriasis

In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.

No Cancer Risk from Psoriatic Arthritis

Inflammmation is a strong risk factor for malignancy. Yet there are mixed results on whether patients with psoriatic arthritis (PsAg) augments the incidence of cancer and all-cause and cause-mortality.

A study from the national British Society for Rheumatology Biologics Register examined the risk of cancer, assessed by standardized incidence ratios (SIRs)  or standardized mortality ratios (SMRs).

Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis

A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious,  hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.

They studied 747 AS patients who initiated TNFI and/or DMARDs between 2001 and 2011 to identify hospitalized infection  coding data and hospital discharge diagnoses.